Michael Heltzen, CEO of eXoZymes Inc. (Nasdaq: EXOZ), recently discussed the company's innovative approach and future plans in an interview as part of Nasdaq's 'Amplify Spotlight' series. Heltzen outlined how eXoZymes develops biosolutions for valuable natural products and their pharmaceutical counterparts, leveraging a foundational science breakthrough that the company was built and IPO'd on last year. He highlighted the firm's alternative financing route and the opportunities it brings for investor engagement and company growth. Looking ahead, Heltzen defined success for eXoZymes as the application of its breakthrough technology across multiple markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.